Pharmaceutical

dsm-firmenich to elevate patient health with launch of advanced formulated CBD drug product intermediate - CBtru®

dsm-firmenich has announced the launch of CBtru® – an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats.

dsm-firmenich partners with bod science to advance science behind first ever cbd-based treatment for insomnia

dsm-firmenich is proud to announce its strategic partnership with Bod Science, an Australian-based pioneer in medical cannabis.

dsm-firmenich and OMG Pharma form strategic collaboration to advance first-of-a-kind CBD-based drugs for insomnia

dsm-firmenich is proud to announce its new strategic collaboration with Oz Medicann Group (OMG), to explore the therapeutic potential of cannabidiol (CBD) bases orally dispersible tablets addressing insomnia.

dsm-firmenich partners with Zerion Pharma a/s to unlock superior patient-centric cannabinoid formulations

dsm-firmenich is proud to announce its strategic partnership with Zerion Pharma, to unlock a new era in cannabinoid innovation.

dsm-firmenich and Brains Bioceutical form exclusive global partnership to unlock the therapeutic potential of cannabinoids in early-stage drug development

Royal dsm-firmenich, a global science-based company active in Nutrition, Health and Sustainable Living, announces it has entered into an exclusive commercial partnership with global leader and pioneer in cannabinoid active pharmaceutical ingredients (APIs), Brains Bioceutical.

dsm-firmenich Builds China Drug Master File Portfolio, Achieving Active Status for Pyridoxine Hydrochloride (Vitamin B6)

Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, has announced that its China Drug Master File (CDMF) for pyridoxine hydrochloride (vitamin B6) has been granted active status. DSM remains the first and only company in the world that can provide both US DMFs and Certificates of Suitability (CEPs) for all 13 vitamins.

dsm-firmenich to debut at CPhI, sharing its vision for purpose-powered solutions for the pharmaceutical industry

Following the merger of two iconic companies – DSM and Firmenich – in May 2023, dsm-firmenich will make its debut at CPHI Barcelona 2023, showcasing its combined strength as an innovator in health, nutrition and care.